The company had reported profit of Rs 159.1 crore in the corresponding period a year ago. Total income of the company rose by 26.13 per cent to Rs 2,044.1 crore as against Rs 1,620.6 crore for the same period year ago, the company said in a regulatory filing. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, said: In Q4FY21 our revenues grew 26 per cent year-on-year to Rs 2,044 crore driven by our biosimilars, research services and generics businesses . Mazumdar-Shaw said the Biocon Group is catering to the countrywide demand for Remdesivir, Itolizumab and CytoSorb. Syngene through its vaccination centre is offering immunisation services for Biocon Group employees as well to others operating in Electronic City, Bengaluru. Despite the challenges posed by the second COVID-19 wave in India, we will endeavour to have safe and uninterrupted operations and enable access to life-saving medicines for our patients and customers, she added.
Biocon posts Rs 257 crore profit for Q4 on strong biosimilar business ANI | Updated: Apr 29, 2021 12:58 IST
Bengaluru (Karnataka) [India], April 29 (ANI): Biopharmaceuticals major Biocon Ltd on Thursday reported net profit of Rs 257 crore in the fourth quarter of FY21, up 95 per cent from Rs 132 crore in Q4 FY20.
The was largely driven by biosimilars, research services and generics businesses. The company s Q4 FY21 consolidated revenue grew 26 per cent to Rs 2,044 crore from Rs 1,621 crore in Q4 FY20.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) was Rs 641 crore versus Rs 382 crore in the same period.
Biocon gained Rs 160 crore arising on fair valuation of Bicara Therapeutics Inc due to loss of control from subsidiary to associate reported under other income for the quarter.
Biocon Biologics New Monoclonal Antibodies Manufacturing Facility Wins ISPE s 2021 Facility of the Year Honorable Mention Award equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Biocon Biologics’ new monoclonal antibodies facility bags ISPE’s 2021 award
April 28, 2021
×
This is the first time that a biopharma company from India has been awarded an ISPE FOYA mention Biocon Biologics Ltd, a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd, has announced that it has been awarded with the 2021 Facility of the Year Award (FOYA) from the International Society for Pharmaceutical Engineering (ISPE).
The company received an Honorable Mention award for its monoclonal antibodies drugs substances manufacturing facility located at Biocon Park.
This is the first time that a biopharmaceutical company from India has been awarded an ISPE FOYA mention. Every year, ISPE’s FOYA programme recognises projects utilising new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines and demonstrate advances in project delivery.
Results: Bioconâs revenue up at Rs 2,044 crore in Q4 of FY21
Results: Bioconâs revenue up at Rs 2,044 crore in Q4 of FY21
Bangalore-based Biocon reported a 26 per cent rise in consolidated revenue from Rs 1,621 crore in Q4FY20 to Rs 2,044 crore in Q4FY 2021. Indian biopharmaceutical company registered a net profit of over 100 per cent, at Rs 254 crore in Q4FY20.
The consolidated revenue grew 14 per cent to Rs 7,360 crore in FY21 from Rs 6,462 crore in FY20. In FY21, the net profit (before exceptional item and discontinuing operations) was at Rs 754 crore was down 4 per cent. The net profit was marginally down by 1 per cent at Rs 740 crore in FY 2021, from Rs 748 crore. While gross research and development was down by 2 per cent quarter on quarter; year on year basis it was up by 19 per cent, at Rs 627 crore.